3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
63
Precursor Cell Lymphoblastic Leukemia-Lymphoma
52
Leukemia, Myeloid, Chronic-Phase
34
Leukemia
30
Leukemia, Myeloid, Acute
18
Leukemia, Lymphocytic, Chronic, B-Cell
13
Blast Crisis
12
Leukemia, Myeloid, Accelerated Phase
9
Recurrence
8
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
7
Burkitt Lymphoma
7
Multiple Myeloma
6
Philadelphia Chromosome
5
Myelodysplastic Syndromes
5
Lymphoma, Non-Hodgkin
5
Hematologic Neoplasms
5
Lymphoma
4
Hodgkin Disease
4
Bronchiolitis Obliterans Syndrome
4
Waldenstrom Macroglobulinemia
3
Sezary Syndrome
3
Mycosis Fungoides
3
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Large-Cell, Anaplastic
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Lymphoma, Extranodal NK-T-Cell
3
Lymphoma, B-Cell, Marginal Zone
3
Interventions
nilotinib
1
Dasatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Substance Withdrawal Syndrome
×
Dasatinib
×
Other hematologic neoplasm
×
Clear all
NCT04147533
2024-11-26
HALF
Masaryk University
Phase 2
Active not recruiting
150 enrolled